Intrathecal medicines
30 results
Applied filters
Hydrocortisone: informing intrathecal risk assessment
19 February 2024Hydrocortisone products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Ziconotide: informing intrathecal risk assessment
19 February 2024Ziconotide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Levobupivacaine: informing intrathecal risk assessment
19 February 2024Levobupivacaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Morphine: informing intrathecal risk assessment
19 February 2024Morphine sulfate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Lidocaine: informing intrathecal risk assessment
19 February 2024Lidocaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Phenol: informing intrathecal risk assessment
19 February 2024Phenol products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Hydrocortisone acetate: informing intrathecal risk assessment
19 February 2024Hydrocortisone acetate products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Ropivacaine: informing intrathecal risk assessment
19 February 2024Ropivacaine products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
Intrathecal administration
All our advice on using intrathecal medicines safely.
Managing an intrathecal chemotherapy service
13 June 2025The intrathecal route is a high-risk route of administration. There are minimum requirements for providing intrathecal chemotherapy.